GlassScriptPhysician profile
Abigail Updike
NPI 1225622673
$4,783.91
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $818 · 2023: $1,654 · 2024: $2,011 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703 · Consulting Fee: $1,063 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.08 |
| Consulting Fee | $1,062.50 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,607.42 | 2022-2024 | Tremfya |
| Abbvie INC. | $1,405.74 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $237.70 | 2023-2024 | |
| Galderma Laboratories, L.P. | $236.82 | 2024-2025 | Aklief |
| E.R. Squibb & Sons, L.L.C. | $207.97 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $180.34 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.60 | 2022-2024 | Spevigo |
| Pfizer INC. | $132.38 | 2022-2024 | |
| Revance Therapeutics, INC. | $122.86 | 2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $86.38 | 2023-2024 | Winlevi, Absorica Ld |
| Almirall LLC | $61.24 | 2022-2024 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $61.11 | 2023 | Dupixent |
| Lilly USA, LLC | $60.40 | 2022-2024 | Olumiant, Taltz |
| Incyte Corporation | $58.15 | 2023-2024 | Opzelura |
| Biofrontera INC. | $34.87 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $29.31 | 2022 | |
| Arcutis Biotherapeutics, INC. | $28.20 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.67 | 2023-2024 | Cabtreo, Jublia |
| Amgen INC. | $24.94 | 2024 | Otezla |
| Journey Medical Corporation | $16.66 | 2023 | |
| Verrica Pharmaceuticals INC. | $14.15 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Updike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.